Literature DB >> 19327386

Rho GTPase function in tumorigenesis.

R Karlsson1, E D Pedersen, Z Wang, Cord Brakebusch.   

Abstract

Malignant tumor cells display uncontrolled proliferation, loss of epithelial cell polarity, altered interactions with neighboring cells and the surrounding extracellular matrix, and enhanced migratory properties. Proteins of the Rho GTPase family regulate all these processes in cell culture and, for that reason, Rho GTPases, their regulators, and their effectors have been suggested to control tumor formation and progression in humans. However, while the tumor-relevant functions of Rho GTPases are very well documented in vitro, we are only now beginning to assess their contribution to cancer in human patients and in animal models. This review will give a very brief overview of Rho GTPase function in general and then focus on in vivo evidence for a role of Rho GTPases in malignant tumors, both in human patients and in genetically modified mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327386     DOI: 10.1016/j.bbcan.2009.03.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  169 in total

1.  RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis.

Authors:  Ellen V Stevens; Natalie Banet; Cercina Onesto; Ana Plachco; Jamie K Alan; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Pei Fen Kuan; Jinsong Liu; C Ryan Miller; Dominico Vigil; Lee M Graves; Channing J Der
Journal:  Small GTPases       Date:  2011-07-01

2.  Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1.

Authors:  Yan Larson; Jianyu Liu; Payton D Stevens; Xin Li; Jing Li; B Mark Evers; Tianyan Gao
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

3.  Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase.

Authors:  Wei Li; Yan Zhang; Richard Bouley; Ying Chen; Toshiyuki Matsuzaki; Paula Nunes; Udo Hasler; Dennis Brown; Hua A Jenny Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-04-20

4.  The Rho GTPase Cdc42 is required for primary mammary epithelial cell morphogenesis in vitro.

Authors:  Kristi Bray; Cord Brakebusch; Tracy Vargo-Gogola
Journal:  Small GTPases       Date:  2011-09-01

5.  Secretory pathway-dependent localization of the Saccharomyces cerevisiae Rho GTPase-activating protein Rgd1p at growth sites.

Authors:  Fabien Lefèbvre; Valérie Prouzet-Mauléon; Michel Hugues; Marc Crouzet; Aurélie Vieillemard; Derek McCusker; Didier Thoraval; François Doignon
Journal:  Eukaryot Cell       Date:  2012-03-23

6.  Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells.

Authors:  Changhwan Yoon; Soo-Jeong Cho; Bülent Arman Aksoy; Do Joong Park; Nikolaus Schultz; Sandra W Ryeom; Sam S Yoon
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

7.  RHOA mutation may be associated with diffuse-type gastric cancer progression, but is it gain or loss?

Authors:  Masahiro Maeda; Toshikazu Ushijima
Journal:  Gastric Cancer       Date:  2015-08-22       Impact factor: 7.370

Review 8.  Cellular and molecular mechanisms underlying blood vessel lumen formation.

Authors:  Marta S Charpentier; Frank L Conlon
Journal:  Bioessays       Date:  2013-12-09       Impact factor: 4.345

9.  Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.

Authors:  Miwako Kakiuchi; Takashi Nishizawa; Hiroki Ueda; Kengo Gotoh; Atsushi Tanaka; Akimasa Hayashi; Shogo Yamamoto; Kenji Tatsuno; Hiroto Katoh; Yoshiaki Watanabe; Takashi Ichimura; Tetsuo Ushiku; Shinichi Funahashi; Keisuke Tateishi; Ikuo Wada; Nobuyuki Shimizu; Sachiyo Nomura; Kazuhiko Koike; Yasuyuki Seto; Masashi Fukayama; Hiroyuki Aburatani; Shumpei Ishikawa
Journal:  Nat Genet       Date:  2014-05-11       Impact factor: 38.330

10.  RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7).

Authors:  Emilie Malissein; Elise Meunier; Isabelle Lajoie-Mazenc; Claire Médale-Giamarchi; Florence Dalenc; Sophie F Doisneau-Sixou
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.